Back to Search Results

11/3/2020

Urodynamics: Indications for the Procedure and Systematic Interpretation

Urinary incontinence evaluation includes a detailed history, physical examination, demonstration of stress incontinence, assessment of urethral mobility, determination of symptom severity, and identification of treatment goals. Patients who screen positive for incontinence should have a urinalysisand a postvoid residual to exclude urinary tract infection and overflow or retention, respectively, before proceeding with treatment.

Urodynamic testing is reserved for complex conditions. Patients with uncomplicated stress urinary incontinence (postvoid residual <150 mL, negative urinalysis, and a positive stress test) do not need to undergo urodynamic testing before surgery. Indications for testing include unclear diagnosis after basic evaluation, failure to improve after initial treatment, prior pelvic floor surgery, or symptoms that do not correlate with physical findings.

Urodynamic testing evaluates lower urinary tract function by measuring urinary storage and voiding functionality. Testing includes uroflowmetry, cystometrography, and urethral pressure profilometry. The first step is to perform uroflowmetry. The patient empties their bladder into a commode connected to a flowmeter. The average woman can empty a full bladder in 15 to 20 seconds with an average flow rate of 20 mL/sec. Voiding dysfunction is diagnosed if the flow rate is less than 15 mL/sec with urine volume retention greater than 200 mL.

Cystometrography diagnoses urinary stress incontinence or overactive bladder. Two catheters are used: one is placed into the bladder to measure bladder pressure (P_ves) and the other is placed in the vagina or rectum to measure abdominal pressure (P_abd). Detrusor pressure (P_det) is calculated by subtracting abdominal pressure from vesicular pressure (P_det = P_ves – P_abd). Five distinct measurements from cystometrography are: intraabdominal pressure, vesicular pressure, detrusor pressure, bladder volume, and saline infusion flow rate. The bladder is incrementally filled with warm saline, and the patient is asked to cough and/or perform a Valsalva maneuver to assess for stress urinary incontinence. Volumes are recorded when the patient feels the urge to void and at maximal void capacity.

The instantaneous bladder pressure is recorded when a patient leaks urine with cough (cough leak point pressure) or Valsalva maneuver (Valsalva leak point pressure). Cough leak point pressure or Valsalva leak point pressure less than 60 cm H₂0 is indicative of intrinsic sphincter deficiency. Pressures higher than these values are an indication that the urethral sphincter is functioning normally and that urethral hypermobility is the cause of stress urinary incontinence.

The diagnosis of overactive bladder (with or without leakage) occurs when there is an acute increase in detrusor pressure during the filling phase of cystometrography. Although there is no set minimum increase to detect a detrusor contraction, there is a distinct rise in detrusor pressure. Sustained rises in detrusor pressureare indicative of noncompliant bladders.  Radiation, advanced interstitial cystitis, or surgery result in a bladder that cannot expand or fill appropriatelyPoorly compliant bladders that reach detrusor pressures above 40 cm H₂0 increase the risk for vesicourethral reflux, hydronephrosis, and kidney damage.  

Urethral pressure profilometry is done at maximum bladder capacity while slowly pulling the pressure catheter along the length of the urethra to record the maximum urethral closing pressure. Maximum urethral closing pressure less than 20 cm H₂0 indicates intrinsic sphincter deficiency.

Further Reading:

Committee Opinion No. 603: Evaluation of uncomplicated stress urinary incontinence in women before surgical treatment. Obstet Gynecol. 2014 Jun;123(6):1403-7. doi: 10.1097/01.AOG.0000450759.34453.31. PMID: 24848922. (Reaffirmed 2018, 2024)

Capobianco, G., Cherchi, P. L., & Dessole, S. Management of Female Stress Urinary Incontinence (2019). Postmenopausal Diseases and Disorders, 145-163.

Initial Publication: November 2020; Revised May 2022; Revised March 2024.

 

********** Notice Regarding Use ************

The Society for Academic Specialists in General Obstetrics and Gynecology, Inc. (“SASGOG”) is committed to accuracy and will review and validate all Pearls on an ongoing basis to reflect current practice.

This document is designed to aid practitioners in providing appropriate obstetric and gynecologic care. Recommendations are derived from major society guidelines and high-quality evidence when available, supplemented by the opinion of the author and editorial board when necessary. It should not be construed as dictating an exclusive course of treatment or procedure to be followed.

Variations in practice may be warranted when, in the reasonable judgment of the treating clinician, such course of action is indicated by the condition of the patient, limitations of available resources, or advances in knowledge or technology. SASGOG reviews the articles regularly; however, its publications may not reflect the most recent evidence. While we make every effort to present accurate and reliable information, this publication is provided “as is” without any warranty of accuracy, reliability, or otherwise, either express or implied. SASGOG does not guarantee, warrant, or endorse the products or services of any firm, organization, or person. Neither SASGOG nor its respective officers, directors, members, employees, or agents will be liable for any loss, damage, or claim with respect to any liabilities, including direct, special, indirect, or consequential damages, incurred in connection with this publication or reliance on the information presented.

Copyright 2024 The Society for Academic Specialists in General Obstetrics and Gynecology, Inc. All rights reserved.  No re-print, duplication or posting allowed without prior written consent.

 

Back to Search Results